Industrial Impact, Medical

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

March 9, 2023

Genetic insights for biopharmaceuticals
For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Spotlight

Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of B-cell lymphomas and rare autoimmune diseases.

OTHER WHITEPAPERS
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

Viral Vectors as a Gene Delivery Vehicle

whitePaper | August 5, 2022

The field of gene and cell therapy is experiencing a renaissance, with innovations in the use of viral vectors as a gene delivery vehicle being a key factor in the field’s growth.

Read More
news image

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

Read More
news image

Synthetic Biology Biotechnology & AgTech

whitePaper | June 8, 2022

For nearly two decades, the Future Today Institute has meticulously researched macro forces of change and the emerging trends that result. Our focus: understanding how these forces and trends will shape our futures.

Read More
news image

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Read More

Spotlight

Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of B-cell lymphomas and rare autoimmune diseases.

Events